Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors
PARIS and PLEASANTON, Calif., Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer survivors, whose survival mechanisms could hold the key to new therapeutic approaches.
Working alongside more than 50 medical institutions, Cure51 intends to collect and analyze tumor tissues from over 1,000 exceptional cancer survivors across 40 countries in the next 18 months. By using Visium HD from 10x Genomics, Cure51 aims to uncover new insights into long-term cancer survival mechanisms and build the first proprietary multi-omics database of exceptional cancer survivors.